153 related articles for article (PubMed ID: 24139839)
1. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
2. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
5. Functional roles of enhancer of zeste homolog 2 in gliomas.
Yin Y; Qiu S; Peng Y
Gene; 2016 Jan; 576(1 Pt 2):189-94. PubMed ID: 26435191
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
7. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
8. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
[TBL] [Abstract][Full Text] [Related]
9. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
10. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
12. Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung.
Bondgaard AL; Poulsen TT; Poulsen HS; Skov BG
Cancer Biomark; 2012; 11(2-3):123-8. PubMed ID: 23011159
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
14. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
15. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
[TBL] [Abstract][Full Text] [Related]
17. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
18. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
19. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
20. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]